

# Eosinophilic Lung Diseases



Vincent Cottin, MD, PhD<sup>a,b,\*</sup>

## KEYWORDS

- Eosinophil • Eosinophilic pneumonia • Interstitial lung disease
- Eosinophilic granulomatosis with polyangiitis • Aspergillus

## KEY POINTS

- Eosinophilic lung diseases may present as eosinophilic pneumonia with chronic or acute onset, or as the more transient Löffler syndrome.
- The diagnosis of eosinophilic pneumonia is based on both characteristic clinical-imaging features and the demonstration of alveolar eosinophilia of at least 25% eosinophils at bronchoalveolar lavage.
- Peripheral blood eosinophilia is present in most eosinophilic lung disorders, but can be absent at presentation in idiopathic acute eosinophilic pneumonia and in patients receiving corticosteroid treatment.
- In Europe and North America, chronic eosinophilic pneumonia is most frequently idiopathic, whereas acute eosinophilic pneumonia is often related to drug or tobacco smoke exposure.
- All possible causes of eosinophilia (especially fungus or parasitic infection, drug or toxic exposure) must be thoroughly investigated.

## DEFINITION AND CLASSIFICATION

### Definition

Eosinophilic lung diseases are a group of diffuse parenchymal lung diseases<sup>1,2</sup> characterized by the prominent infiltration of the lung interstitium and the alveolar spaces by polymorphonuclear eosinophils, with conservation of the lung architecture. As a corollary, a common denominator of eosinophilic lung diseases is represented by a dramatic response to systemic corticosteroid therapy and healing without any sequelae in most cases, despite frequent impressive impairment of lung function at presentation.

Blood *eosinophilia* is defined by an eosinophil blood cell count greater than  $0.5 \times 10^9/L$ , and *hypereosinophilia* by an eosinophil blood cell

count of greater than  $1.5 \times 10^9$  on 2 examinations over at least a 1-month interval.<sup>3–5</sup> Alveolar eosinophilia is defined by differential cell count of at least 25% eosinophils at bronchoalveolar lavage (BAL), and typically greater than 40%.<sup>4</sup>

### Classification

Eosinophilic lung disorders can present as acute or chronic pneumonia or as the transient Löffler syndrome, which is most commonly of parasitic origin (**Box 1**). The main causes include exposure to drugs or toxins and fungal infection; however, chronic eosinophilic pneumonia is most often idiopathic, and acute eosinophilic pneumonia most often is related to drugs or tobacco smoking. Eosinophilic lung disorders occurring in the

Conflicts of Interest/Financial Support: Hospices Civils de Lyon, Université Lyon I.

<sup>a</sup> Hospices Civils de Lyon, Louis Pradel Hospital, National Reference Center for Rare Pulmonary Diseases, Department of Respiratory Diseases, F-69677 Lyon, France; <sup>b</sup> Univ Lyon, Université Lyon I, INRA, UMR754, 8 avenue Rockefeller, F-69008 Lyon, France

\* Hospices Civils de Lyon, Louis Pradel Hospital, National Reference Center for Rare Pulmonary Diseases, Department of Respiratory Diseases, F-69677 Lyon, France

E-mail address: [vincent.cottin@chu-lyon.fr](mailto:vincent.cottin@chu-lyon.fr)

Clin Chest Med 37 (2016) 535–556

<http://dx.doi.org/10.1016/j.ccm.2016.04.015>

0272-5231/16/\$ – see front matter © 2016 Elsevier Inc. All rights reserved.

**Box 1****Classification of the eosinophilic lung diseases in clinical practice***Eosinophilic pneumonias of unknown cause*

Solitary idiopathic eosinophilic pneumonias

Idiopathic chronic eosinophilic pneumonia

Idiopathic acute eosinophilic pneumonia

Eosinophilic pneumonia in systemic syndromes

Eosinophilic granulomatosis with polyangiitis

Idiopathic hypereosinophilic syndromes (lymphocytic or myeloproliferative variant)

*Eosinophilic pneumonias of known cause*

Allergic bronchopulmonary aspergillosis and related syndromes

Eosinophilic pneumonias of parasitic origin

Eosinophilic pneumonias of other infectious causes

Drug-induced eosinophilic pneumonias

*Eosinophilic airways diseases*

Eosinophilic asthma

Hypereosinophilic asthma

Idiopathic hypereosinophilic constrictive bronchiolitis

*Other pulmonary syndromes with possible eosinophilia*

Organizing pneumonia, idiopathic pulmonary fibrosis, Langerhans cell histiocytosis, malignancies, and so forth

context of systemic conditions suggest the diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) or the idiopathic hypereosinophilic syndromes.

**PATHOPHYSIOLOGY*****Recruitment of Eosinophils to the Lung***

Blood and tissue eosinophilia have long been identified as major players in immunity against parasites and in the pathogenesis of allergic diseases.<sup>6</sup> Following differentiation of precursor cells in the bone marrow under the action of several cytokines, including interleukin (IL)-5, IL-3, and granulocyte macrophage colony-stimulating factor (GM-CSF),<sup>7-9</sup> eosinophils are recruited in the blood and tissue, including the lung in response to circulating IL-5, eotaxins, and the C-C chemokine receptor-3 (CCR3). Because recruitment of eosinophils to tissues is organ-specific, tissue and blood eosinophilia are not necessarily

associated. The prominence of IL-5 in eosinophil differentiation and recruitment has led to the development of anti-IL-5 monoclonal antibodies to selectively target the eosinophil lineage in humans with asthma.<sup>10-14</sup>

***Eosinophils and Immunity***

Eosinophils are active participants in innate immunity. They interact with basophils, endothelial cells, macrophages, platelets, fibroblasts, and mast cells through cell membrane signaling molecules and receptors including Toll-like receptors and receptors for cytokines, immunoglobulins, and complement.<sup>7-9,15</sup> Activated eosinophils release proinflammatory cytokines, arachidonic acid-derived mediators, enzymes, reactive oxygen species, complement proteins, chemokines, chemoattractants, metalloproteases, and cationic proteins. The latter are released by degranulation of activated eosinophils and exert a variety of effects, including direct cytotoxicity, upregulation of chemoattraction, expression of adhesion molecules, regulation of vascular permeability, and contraction of smooth muscle cells.<sup>7-9</sup> Activated, degranulated ("hypodense") eosinophils can be found in the bronchoalveolar lavage (BAL)<sup>16,17</sup> and the lung tissue<sup>18</sup> of patients with eosinophilic pneumonias. Tissue damage mediated by eosinophil cationic proteins is exemplified by the cardiac lesions that occur in the hypereosinophilic syndrome or in tropical eosinophilia.<sup>15</sup>

Eosinophils are also involved in adaptive immunity against bacteria, viruses, and tumors through interaction with T-lymphocytes.<sup>7-9</sup> They present antigens to T-helper-2 cells in tissues and in the draining lymph nodes in the context of major histocompatibility complex class II, thereby inducing T cell development, activation, and migration to sites of inflammation. Eosinophils secrete IL-4 and IL-13, amplifying the T-helper-2 response in the lung, and in turn are recruited and activated by T-helper-2 cell-derived cytokines (IL-4, IL-5, and IL-13).

**IDIOPATHIC CHRONIC EOSINOPHILIC PNEUMONIA**

First characterized by Carrington and colleagues,<sup>19</sup> idiopathic chronic eosinophilic pneumonia (ICEP) is characterized by the onset over a few weeks of cough, dyspnea, malaise, and weight loss, with diffuse pulmonary infiltrates.

***Epidemiology and Risk Factors***

Although it is a rare disease, representing fewer than 3% of cases of various interstitial lung

Download English Version:

<https://daneshyari.com/en/article/4207020>

Download Persian Version:

<https://daneshyari.com/article/4207020>

[Daneshyari.com](https://daneshyari.com)